NEW YORK – Diagnostics company Precipio announced on Thursday that it has received New York state approval for its Hemescreen MPN panel hematologic malignancy test.
The molecular test uses the firm's high resolution melt technology to detect hematologic malignancies. With the state approval, the real-time PCR-based assay for myeloproliferative disorders can now be used by New York-based physician-owned labs as a laboratory-developed test.
Precipio's customer New York Cancer and Blood Specialists (NYCB) validated the test and submitted it to the New York State Department of Health. Precipio noted in a statement that NYCB could potentially generate seven-figure revenues for Precipio.
The New Haven, Connecticut-based company has an anemia panel and an acute myeloid leukemia panel for use with its Hemescreen technology.
Although the state approval was only for its MPN panel, other panels using the tech can be submitted by NYCB as add-ons under the umbrella of the Hemescreen platform, a spokesperson for the company said.